{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:01:41Z","timestamp":1740106901627,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00277-021-04709-3","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T07:02:52Z","timestamp":1636527772000},"page":"1149-1152","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Epstein-Barr virus\u2013positive diffuse large B-cell lymphoma after frontline brentuximab vedotin treatment of classical Hodgkin lymphoma"],"prefix":"10.1007","volume":"101","author":[{"given":"Eric","family":"Tse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rex","family":"Au-Yeung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Chau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Yan","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Loong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8156-6978","authenticated-orcid":false,"given":"Yok-Lam","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,10]]},"reference":[{"issue":"4","key":"4709_CR1","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1056\/NEJMoa1708984","volume":"378","author":"JM Connors","year":"2018","unstructured":"Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Ill\u00e9s \u00c1, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J, ECHELON-1 Study Group (2018) Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med 378(4):331\u2013344","journal-title":"N Engl J Med"},{"issue":"10","key":"4709_CR2","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1182\/blood.2019003127","volume":"135","author":"DJ Straus","year":"2020","unstructured":"Straus DJ, D\u0142ugosz-Danecka M, Alekseev S, Ill\u00e9s \u00c1, Picardi M, Lech-Maranda E, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Ramchandren R, Zinzani PL, Hutchings M, Connors JM, Radford J, Munoz J, Kim WS, Advani R, Ansell SM, Younes A, Miao H, Liu R, Fenton K, Forero-Torres A, Gallamini A (2020) Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood 135(10):735\u2013742","journal-title":"Blood"},{"issue":"16","key":"4709_CR3","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1182\/bloodadvances.2021004515","volume":"5","author":"E Bourbon","year":"2021","unstructured":"Bourbon E, Maucort-Boulch D, Fontaine J, Mauduit C, Sesques P, Safar V, Ferrant E, Golfier C, Ghergus D, Karlin L, Lazareth A, Bouafia F, Pica GM, Orsini-Piocelle F, Rocher C, Gros FX, Parrens M, Dony A, Rossi C, Ghesqui\u00e8res H, Bachy E, Traverse-Glehen A, Sarkozy C (2021) Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified. Blood Adv 5(16):3227\u20133239","journal-title":"Blood Adv"},{"key":"4709_CR4","first-page":"304","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"S Nakamura","year":"2017","unstructured":"Nakamura S, Jaffe ES, Swerdlow SH (2017) EBV-positive diffuse large B-cell lymphoma, not otherwise specified (NOS). In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, Siebert R (eds) WHO classification of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer, Lyon, pp 304\u2013306"},{"issue":"9","key":"4709_CR5","doi-asserted-by":"publisher","first-page":"e603","DOI":"10.1038\/bcj.2017.85","volume":"7","author":"CA van der Weyden","year":"2017","unstructured":"van der Weyden CA, Pileri SA, Feldman AL, Whisstock J, Prince HM (2017) Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions. Blood Cancer J 7(9):e603","journal-title":"Blood Cancer J"},{"issue":"8","key":"4709_CR6","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1080\/14740338.2016.1198775","volume":"15","author":"DW Raisch","year":"2016","unstructured":"Raisch DW, Rafi JA, Chen C, Bennett CL (2016) Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA\u2019s adverse event reporting system. Expert Opin Drug Saf 15(8):1003\u20131011","journal-title":"Expert Opin Drug Saf"},{"issue":"16","key":"4709_CR7","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1002\/cncr.28712","volume":"120","author":"KR Carson","year":"2014","unstructured":"Carson KR, Newsome SD, Kim EJ, Wagner-Johnston ND, von Geldern G, Moskowitz CH, Moskowitz AJ, Rook AH, Jalan P, Loren AW, Landsburg D, Coyne T, Tsai D, Raisch DW, Norris LB, Bookstaver PB, Sartor O, Bennett CL (2014) Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer 120(16):2464\u20132471","journal-title":"Cancer"},{"issue":"18","key":"4709_CR8","doi-asserted-by":"publisher","first-page":"6565","DOI":"10.1002\/cam4.3298","volume":"9","author":"MPE Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 MPE, Carde P, Viviani S, Bellei M, Fortpied C, Hutchings M, Gianni AM, Brice P, Casasnovas O, Gobbi PG, Zinzani PL, Dupuis J, Iannitto E, Rambaldi A, Bri\u00e8re J, Cl\u00e9ment-Filliatre L, Heczko M, Valagussa P, Douxfils J, Depaus J, Federico M, Mounier N (2020) Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: a pooled analysis of four randomized trials. Cancer Med 9(18):6565\u20136575","journal-title":"Cancer Med"},{"issue":"7","key":"4709_CR9","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.ejca.2005.01.006","volume":"41","author":"G Bonadonna","year":"2005","unstructured":"Bonadonna G, Viviani S, Bonfante V, Gianni AM, Valagussa P (2005) Survival in Hodgkin\u2019s disease patients\u2013report of 25 years of experience at the Milan Cancer Institute. Eur J Cancer 41(7):998\u20131006","journal-title":"Eur J Cancer"},{"issue":"6","key":"4709_CR10","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1200\/JCO.2009.25.4961","volume":"28","author":"AM Evens","year":"2010","unstructured":"Evens AM, David KA, Helenowski I, Nelson B, Kaufman D, Kircher SM, Gimelfarb A, Hattersley E, Mauro LA, Jovanovic B, Chadburn A, Stiff P, Winter JN, Mehta J, Van Besien K, Gregory S, Gordon LI, Shammo JM, Smith SE, Smith SM (2010) Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol 28(6):1038\u20131046","journal-title":"J Clin Oncol"},{"key":"4709_CR11","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3389\/fonc.2019.00683","volume":"9","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Xu Z, Lin W, Duan Y, Lu C, Liu W, Su W, Yan Y, Liu H, Liu L, Zhong M, Zhou J, Zhu H (2019) Comprehensive genomic profiling of EBV-positive diffuse large B-cell lymphoma and the expression and clinicopathological correlations of some related genes. Front Oncol 9:683","journal-title":"Front Oncol"},{"issue":"1","key":"4709_CR12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/bjh.14633","volume":"178","author":"T Menter","year":"2017","unstructured":"Menter T, Juskevicius D, Alikian M, Steiger J, Dirnhofer S, Tzankov A, Naresh KN (2017) Mutational landscape of B-cell post-transplant lymphoproliferative disorders. Br J Haematol 178(1):48\u201356","journal-title":"Br J Haematol"},{"issue":"11","key":"4709_CR13","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/s41579-019-0249-7","volume":"17","author":"C M\u00fcnz","year":"2019","unstructured":"M\u00fcnz C (2019) Latency and lytic replication in Epstein-Barr virus-associated oncogenesis. Nat Rev Microbiol 17(11):691\u2013700","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"4709_CR14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13045-019-0814-6","volume":"12","author":"B Li","year":"2019","unstructured":"Li B, Chng WJ (2019) EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications. J Hematol Oncol 12(1):118","journal-title":"J Hematol Oncol"},{"issue":"4","key":"4709_CR15","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.chom.2017.09.001","volume":"22","author":"S Jiang","year":"2017","unstructured":"Jiang S, Zhou H, Liang J, Gerdt C, Wang C, Ke L, Schmidt SCS, Narita Y, Ma Y, Wang S, Colson T, Gewurz B, Li G, Kieff E, Zhao B (2017) The Epstein-Barr Virus regulome in lymphoblastoid cells. Cell Host Microbe 22(4):561-573.e4","journal-title":"Cell Host Microbe"},{"issue":"2","key":"4709_CR16","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.2651","volume":"18","author":"P Ntziachristos","year":"2012","unstructured":"Ntziachristos P, Tsirigos A, Van Vlierberghe P, Nedjic J, Trimarchi T, Flaherty MS, Ferres-Marco D, da Ros V, Tang Z, Siegle J, Asp P, Hadler M, Rigo I, De Keersmaecker K, Patel J, Huynh T, Utro F, Poglio S, Samon JB, Paietta E, Racevskis J, Rowe JM, Rabadan R, Levine RL, Brown S, Pflumio F, Dominguez M, Ferrando A, Aifantis I (2012) Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med 18(2):298\u2013301","journal-title":"Nat Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04709-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-021-04709-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04709-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T09:05:57Z","timestamp":1649408757000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-021-04709-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,10]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["4709"],"URL":"https:\/\/doi.org\/10.1007\/s00277-021-04709-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2021,11,10]]},"assertion":[{"value":"17 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The patient gave informed consent to treatment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}